Men With Genetic Risk of CRC May Lower Risk Via Healthy Lifestyle
Adopting healthy lifestyle can cut 25-year risk for the disease from 29 to 13 percent.
Adopting healthy lifestyle can cut 25-year risk for the disease from 29 to 13 percent.
A recent study undertaken sought to examine the effects of chemotherapy on bladder cancer cells and possible connections to later treatment resistance.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.
Patient-derived cancer cell lines contain most of the genetic changes found in patients’ tumors and could be used to determine tumor response to treatment, increasing the success rate of new personalized therapies for cancer.
A subset of tumor-associated neutrophils (TANs) has hybrid characteristics of both neutrophils and antigen-presenting cells in samples from early stage human lung cancers.
Circulating tumor DNA (ctDNA) has shorter fragment sizes than DNA fragments from healthy cells that have died, and this may increase the clinical utility of liquid biopsies.
Genetic biomarkers from tumor DNA circulating in the bloodstream could indicate the risk for recurrence of colorectal cancer and the efficacy of chemotherapy after surgery.
Researchers discovered that changes in the bone marrow needed for multiple myeloma to grow have already taken hold in patients with MGUS.
Genetic mutations affecting the immune system were identified in patients who develop more than one CRC tumor at the same time, and understanding how these cancers develop could improve therapy targeting.